TECHNOLOGY NETWORKS | Long-Lasting Male Contraceptive Vasalgel® Enters Human Trials
ORIGINALLY POSTED ON: TECHNOLOGY NETWORKS
Plan A™ by NEXT Life Sciences offers a reversible, non-hormonal male contraceptive using Vasalgel®.
The notion that today’s contraceptives grant genuine reproductive autonomy, for men or women, contradicts the reality of their limitations. With over 40% of unintended pregnancies resulting from inconsistent or incorrect contraceptive use, it is time to recognize that existing methods are insufficient.
Incorrect contraceptive use includes condom mishaps, with real-world failure rates of over 13% observed. Men are left with just two additional options: vasectomy, an invasive procedure with variable reversal success, and withdrawal, which is equally risky with regard to efficacy. These partial solutions leave reproductive autonomy out of reach.
With demand for novel male contraceptives on the rise, pioneers are working on various forms to provide a wider range of options, from oral tablets to topical creams and long-lasting injectables.
Technology Networks spoke with Dr. Darlene Walley, chief executive officer at NEXT Life Sciences. The company is taking an innovative approach in developing a non-hormonal, long-acting, reversible hydrogel, able to filter sperm from semen to prevent pregnancy and provide a novel family planning solution.